Your browser doesn't support javascript.
loading
Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's Reassessment and Uptake Working Group.
Dai, Wei Fang; Arciero, Vanessa; Craig, Erica; Fraser, Brent; Arias, Jessica; Boehm, Darryl; Bosnic, Nevzeta; Caetano, Patricia; Chambers, Carole; Jones, Barry; Lungu, Elena; Mitera, Gunita; Potashnik, Tanya; Reiman, Anthony; Ritcher, Trevor; Beca, Jaclyn M; Denburg, Avram; Mercer, Rebecca E; Parmar, Ambica; Tadrous, Mina; Takhar, Pam; Chan, Kelvin K W.
Afiliação
  • Dai WF; Temerty Faculty of Medicine, University of Toronto, 1 King's College Circle, Toronto, ON M5S 1A8, Canada.
  • Arciero V; Canadian Centre for Applied Research in Cancer Control, Toronto, ON M5G 2L3, Canada.
  • Craig E; Temerty Faculty of Medicine, University of Toronto, 1 King's College Circle, Toronto, ON M5S 1A8, Canada.
  • Fraser B; New Brunswick Cancer Network, Saint John, NB E2J 3S4, Canada.
  • Arias J; Canadian Agency for Drugs and Technologies in Health, Ottawa, ON K1S 5S8, Canada.
  • Boehm D; Ontario Health (CCO), Toronto, ON M5G 2L7, Canada.
  • Bosnic N; Saskatchewan Cancer Agency, Regina, SK S4W 0G3, Canada.
  • Caetano P; Patented Medicine Prices Review Board, Ottawa, ON K1P 1C1, Canada.
  • Chambers C; Government of Manitoba, Winnipeg, MB R3B 3M9, Canada.
  • Jones B; Alberta Health Services, Edmonton, AB T5J 3E4, Canada.
  • Lungu E; Health Canada, Ottawa, ON K1Y 4X2, Canada.
  • Mitera G; Patented Medicine Prices Review Board, Ottawa, ON K1P 1C1, Canada.
  • Potashnik T; Canadian Association of Provincial Cancer Agencies, Toronto, ON M5H 1J9, Canada.
  • Reiman A; Patented Medicine Prices Review Board, Ottawa, ON K1P 1C1, Canada.
  • Ritcher T; Department of Medicine, Dalhousie University, Halifax, NS B3H 2Y9, Canada.
  • Beca JM; Department of Biology, University of New Brunswick, Fredericton, NB E3B 5A3, Canada.
  • Denburg A; Department of Oncology, Saint John Regional Hospital, Saint John, NB E2L 42L, Canada.
  • Mercer RE; Canadian Agency for Drugs and Technologies in Health, Ottawa, ON K1S 5S8, Canada.
  • Parmar A; Canadian Centre for Applied Research in Cancer Control, Toronto, ON M5G 2L3, Canada.
  • Tadrous M; Ontario Health (CCO), Toronto, ON M5G 2L7, Canada.
  • Takhar P; The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada.
  • Chan KKW; Canadian Centre for Applied Research in Cancer Control, Toronto, ON M5G 2L3, Canada.
  • On Behalf Of The CanREValue Collaboration Reassessment And Uptake Working Group; Ontario Health (CCO), Toronto, ON M5G 2L7, Canada.
Curr Oncol ; 28(5): 4174-4183, 2021 10 16.
Article em En | MEDLINE | ID: mdl-34677272
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Temas: ECOS / Avaliacao_tecnologia Bases de dados: MEDLINE Assunto principal: Neoplasias / Antineoplásicos Tipo de estudo: Health_technology_assessment / Prognostic_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: Curr Oncol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Canadá
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Temas: ECOS / Avaliacao_tecnologia Bases de dados: MEDLINE Assunto principal: Neoplasias / Antineoplásicos Tipo de estudo: Health_technology_assessment / Prognostic_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: Curr Oncol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Canadá